
Azitra Shifts Focus to Cosmetic Proteins and Cancer-Associated Rashes
Clinical-stage biotech Azitra is pivoting its core strategy toward high-value cosmetic proteins and dermatological therapies, reporting a $3.3 million net loss for the second quarter of 2026. The company is actively narrowing its focus to prioritize its most commercially viable programs while scaling back on Netherton syndrome research.





















